.Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AB51_HeparinCombinations.HeparinCombinations .Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AB51_HeparinCombinations.HeparinCombinations| name: | HeparinCombinations |
| ATC code: | B01AB51 | route: | intravenous |
| n-compartments | 1 |
Heparin combinations are preparations containing heparin (an anticoagulant) with one or more additional active substances. Heparin is used primarily for the prevention and treatment of thromboembolic disorders such as deep vein thrombosis, pulmonary embolism, and during procedures requiring anticoagulation. It is a widely approved and used drug in both prophylaxis and treatment of clotting disorders.
Pharmacokinetic parameters reported for adult patients following intravenous administration of heparin in combination with other agents (e.g., sodium, or in multi-component antithrombotic therapies).
Bateman, RM, et al., & Prandi, E (2016). 36th International Symposium on Intensive Care and Emergency Medicine : Brussels, Belgium. 15-18 March 2016. Critical care (London, England) 20(Suppl 2) 94–None. DOI:10.1186/s13054-016-1208-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27885969
Hermiz, J, et al., & Toquica Gahona, C (2025). Apixaban Failure in A Post-Bariatric Surgery Female Patient with Thoracic Aortic Thrombus Secondary to Covid-19. European journal of case reports in internal medicine 12(4) 005254–None. DOI:10.12890/2025_005254 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40270670
Laham, RJ, et al., & Simons, M (1999). Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug metabolism and disposition: the biological fate of chemicals 27(7) 821–826. PUBMED:https://pubmed.ncbi.nlm.nih.gov/10383927